603456 九洲药业
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入1,475,744-15.73%5,523,4185,445,1054,063,1822,647,284
减:营业总成本1,168,180-13.79%4,275,8354,281,4543,332,4362,243,734
    其中:营业成本973,336-11.92%3,443,4933,557,8162,709,0511,654,390
               财务费用(18,888)-339.58%(75,635)(86,168)37,19591,661
               资产减值损失(108)-99.71%(78,204)(59,326)(50,811)(22,167)
公允价值变动收益------(35,222)(1,390)35,973
投资收益(2,342)-64.06%(19,364)2,07061,0684,987
    其中:对联营企业和合营企业的投资收益(2,342)43.86%(7,756)591,1992,469
营业利润280,087-19.85%1,175,7711,107,912753,635456,149
利润总额280,042-19.87%1,180,6421,103,822744,740449,902
减:所得税费用43,869-37.35%149,270182,848110,58970,015
净利润236,173-15.49%1,031,372920,973634,151379,888
减:非控股权益(586)-52.63%(1,884)(197)250(697)
股东净利润236,759-15.65%1,033,256921,170633,901380,585

市场价值指针
每股收益 (元) *0.260-18.75%1.1601.1100.7700.470
每股派息 (元) *----0.5000.4000.2500.200
每股净资产 (元) *9.6337.49%9.4076.3495.4973.829
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容